Filters
Survivors of COVID-19 remain at risk of long-term cardiovascular events, including elevated blood pressure (BP) and endothelial dysfunction, reveals a study.
A recent study has shown 100-percent engagement in care and viral suppression among 25 adolescents and youth with HIV (AYHIV) being treated with long-acting injectable (LAI) cabotegravir/rilpivirine (CAB/RPV) during follow-up.
The use of baloxavir marboxil demonstrates good tolerability in children aged <1 year, with no new safety signals seen, according to a study.
Maternal influenza vaccination during pregnancy appears to reduce the incidence of infection in infants, with the protective effect being more pronounced when vaccination is administered in the second or third trimester, according to a study.
The use of SGLT-2 inhibitors does not appear to pose an elevated risk of urinary tract infection (UTI) among male veterans with type 2 diabetes (T2D), a recent study has shown.
COVID-19 appears to have adverse consequences for patients with cancer, including increased hospitalization, treatment disruption, and death, according to a study.
Maternal immunization with the bivalent respiratory syncytial virus (RSV) prefusion F vaccine (RSVpreF) helps lower the incidence of RSV-related lower respiratory tract disease (LRTD) and severe LRTD leading to hospitalization among infants from birth through age 6 months, according to real-world data from the BERNI study.
In patients with invasive fungal disease (IFD) who have few or no treatment options, olorofim demonstrates efficacy and good tolerability, according to the results of a single-arm, open-label phase IIb study.
Patients with cancer who have received COVID-19 booster vaccinations are better protected against severe disease, according to real-world data from four healthcare systems in the US.
Updated results from the phase IIIB HARMONIE trial demonstrate sustained efficacy of the long-acting monoclonal antibody nirsevimab against respiratory syncytial virus-associated lower respiratory tract infection (RSV-LRTI) hospitalization through day 181 post-dose.
